Product variants and interchangeability

Pharmaceutical equivalence, alternatives and therapeutic equivalence

FDA’s Orange Book distinguishes pharmaceutical equivalents, pharmaceutical alternatives and therapeutic equivalents. Pharmaceutical equivalents use the identical active ingredient in the same dosage form and route and meet applicable standards; therapeutic equivalence additionally depends on approval and evidence such as bioequivalence under the relevant FDA framework.

WHO likewise treats interchangeability of multisource products as an evidence-based regulatory conclusion. These definitions demonstrate why a shared generic name alone is not enough.

Variant details that can change the comparison

• Salt, ester or other active-substance form.
• Strength and its denominator.
• Dosage form and route.
• Immediate, delayed, gastro-resistant, modified or extended release.
• Concentration, fill volume and unit-dose basis.
• Device, inhaler, pen, cartridge or compatible consumable.
• Excipients or container-closure features when they affect performance or safety.

Different strengths within one manufacturer’s line can still be pharmaceutical alternatives rather than automatically interchangeable units.

Interchangeability requires product-specific evidence

Regulators may require in vivo bioequivalence, in vitro evidence, a biowaiver or other product-specific demonstrations depending on the dosage form and risk. The comparator product, study design and acceptance framework are part of that conclusion.

Do not copy a therapeutic-equivalence code, biowaiver conclusion or comparator relationship from another product. The evidence belongs to the application and products for which the regulator made the determination.

How to compare a development portfolio record

First preserve the controlled Luang catalogue identity exactly. Then list unresolved fields. External labels or databases can show why a distinction matters, but they should remain attributed context until the Luang-specific dossier, label or specification resolves the field.

Where a record lists more than one proposed variant, treat them as separate proposed presentations. Do not assume that dose conversion, release behaviour, storage or clinical use transfers between them.

A safe comparison decision tree

1. Do active substance form, dosage form, route and strength match?
2. Do release characteristics and relevant device/container features match?
3. Is the comparator and jurisdiction explicitly identified?
4. Is there regulator-accepted evidence establishing the claimed equivalence or interchangeability?
5. If any answer is missing, describe the products as different or unresolved rather than interchangeable.